Chlorzoxazone is a centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. Chlorzoxazone is a muscle relaxant. The physiologic effect of chlorzoxazone is by means of centrally-mediated muscle relaxation.
Chlorzoxazone is a benzoxazolone derivative with mild sedative and centrally-acting muscle relaxant activities. Although its exact mechanism of action is unknown chlorzoxazone(cz) appears to act at the spinal cord and subcortical levels of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasms. This agent is extensively hydroxylated by cytochrome p450 2e1 (cyp2e1) to 6-hydroxychlorzoxazone (hcz), 11, 12 which is subsequently glucuronidated and eliminated renally. Highly selective for cyp2e1, cz may be used as a selective probe for phenotyping cyp2e1 in humans; the ratio of hcz-to-cz plasma concentrations obtained 2 to 4 hours after oral administration of cz may be used as a phenotypic measure of cyp2e1 enzymatic activity

Chlorzoxazone is a centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. Chlorzoxazone is a muscle relaxant. The physiologic effect of chlorzoxazone is by means of centrally-mediated muscle relaxation.
Chlorzoxazone is a benzoxazolone derivative with mild sedative and centrally-acting muscle relaxant activities. Although its exact mechanism of action is unknown chlorzoxazone(cz) appears to act at the spinal cord and subcortical levels of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasms. This agent is extensively hydroxylated by cytochrome p450 2e1 (cyp2e1) to 6-hydroxychlorzoxazone (hcz), 11, 12 which is subsequently glucuronidated and eliminated renally. Highly selective for cyp2e1, cz may be used as a selective probe for phenotyping cyp2e1 in humans; the ratio of hcz-to-cz plasma concentrations obtained 2 to 4 hours after oral administration of cz may be used as a phenotypic measure of cyp2e1 enzymatic activity